PLYMOUTH MEETING, Pa., Nov. 16, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management team will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY on Thursday, November 30, 2023, at 9:00 a.m. ET.

Harmony Biosciences logo (PRNewsfoto/Harmony Biosciences)

A webcast of the fireside chat will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com 

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-participate-in-piper-sandler-35th-annual-healthcare-conference-301989769.html

SOURCE Harmony Biosciences

Copyright 2023 PR Newswire

Harmony Biosciences (NASDAQ:HRMY)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Harmony Biosciences.
Harmony Biosciences (NASDAQ:HRMY)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Harmony Biosciences.